258 related articles for article (PubMed ID: 35235866)
1. A silica-based antioxidant nanoparticle for oral delivery of Camptothecin which reduces intestinal side effects while improving drug efficacy for colon cancer treatment.
Nguyen-Trinh QN; Trinh KXT; Trinh NT; Vo VT; Li N; Nagasaki Y; Vong LB
Acta Biomater; 2022 Apr; 143():459-470. PubMed ID: 35235866
[TBL] [Abstract][Full Text] [Related]
2. Newly Designed Silica-Containing Redox Nanoparticles for Oral Delivery of Novel TOP2 Catalytic Inhibitor for Treating Colon Cancer.
Vong LB; Kimura S; Nagasaki Y
Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28736844
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy.
Tran HT; Vong LB; Nishikawa Y; Nagasaki Y
J Control Release; 2022 May; 345():880-891. PubMed ID: 35395328
[TBL] [Abstract][Full Text] [Related]
4. Improving silymarin oral bioavailability using silica-installed redox nanoparticle to suppress inflammatory bowel disease.
Nguyen TT; Trinh NT; Tran HN; Tran HT; Le PQ; Ngo DN; Tran-Van H; Van Vo T; Vong LB; Nagasaki Y
J Control Release; 2021 Mar; 331():515-524. PubMed ID: 33616078
[TBL] [Abstract][Full Text] [Related]
5. Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo.
Babaei M; Abnous K; Taghdisi SM; Taghavi S; Sh Saljooghi A; Ramezani M; Alibolandi M
Eur J Pharm Biopharm; 2020 Nov; 156():84-96. PubMed ID: 32882423
[TBL] [Abstract][Full Text] [Related]
6. Silica-installed redox nanoparticles for novel oral nanotherapeutics - improvement in intestinal delivery with anti-inflammatory effects.
Hossain MA; Yamashita M; Vong LB; Ikeda Y; Nagasaki Y
J Drug Target; 2014 Aug; 22(7):638-47. PubMed ID: 24955616
[TBL] [Abstract][Full Text] [Related]
7. Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin.
Tang MQ; Trinh NT; Vu D; Nguyen TT; Dong HT; Vo TV; Vong LB
ADMET DMPK; 2023; 11(4):551-560. PubMed ID: 37937241
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy and gastrointestinal biodistribution of polycationic nanoparticles for oral camptothecin delivery in early and late-stage colorectal tumor-bearing animal model.
Ünal S; Can Öztürk S; Bilgiç E; Yanık H; Korkusuz P; Aktaş Y; Benito JM; Esendağlı G; Bilensoy E
Eur J Pharm Biopharm; 2021 Dec; 169():168-177. PubMed ID: 34700001
[TBL] [Abstract][Full Text] [Related]
9. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation.
Botella P; Abasolo I; Fernández Y; Muniesa C; Miranda S; Quesada M; Ruiz J; Schwartz S; Corma A
J Control Release; 2011 Dec; 156(2):246-57. PubMed ID: 21756949
[TBL] [Abstract][Full Text] [Related]
10. A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment.
Zhang Q; Zhang F; Li S; Liu R; Jin T; Dou Y; Zhou Z; Zhang J
Theranostics; 2019; 9(13):3732-3753. PubMed ID: 31281510
[TBL] [Abstract][Full Text] [Related]
11. Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer.
Xiao B; Viennois E; Chen Q; Wang L; Han MK; Zhang Y; Zhang Z; Kang Y; Wan Y; Merlin D
ACS Nano; 2018 Jun; 12(6):5253-5265. PubMed ID: 29860836
[TBL] [Abstract][Full Text] [Related]
12. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
13. Development of silica-containing redox nanoparticles for medical applications.
Yoshitomi T; Nagasaki Y
Biomater Sci; 2015 Jun; 3(6):810-5. PubMed ID: 26221840
[TBL] [Abstract][Full Text] [Related]
14. Preparation of camptothecin-loaded targeting nanoparticles and their antitumor effects on hepatocellular carcinoma cell line H22.
Yang A; Liu Z; Yan B; Zhou M; Xiong X
Drug Deliv; 2016 Jun; 23(5):1699-706. PubMed ID: 25148540
[TBL] [Abstract][Full Text] [Related]
15. Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer.
Vong LB; Yoshitomi T; Matsui H; Nagasaki Y
Biomaterials; 2015 Jul; 55():54-63. PubMed ID: 25934452
[TBL] [Abstract][Full Text] [Related]
16. ROS-cleavable diselenide nanomedicine for NIR-controlled drug release and on-demand synergistic chemo-photodynamic therapy.
Zhu R; He Q; Li Z; Ren Y; Liao Y; Zhang Z; Dai Q; Wan C; Long S; Kong L; Fan W; Yu W
Acta Biomater; 2022 Nov; 153():442-452. PubMed ID: 36179978
[TBL] [Abstract][Full Text] [Related]
17. Chondroitin sulfate-functionalized polymeric nanoparticles for colon cancer-targeted chemotherapy.
Zu M; Ma L; Zhang X; Xie D; Kang Y; Xiao B
Colloids Surf B Biointerfaces; 2019 May; 177():399-406. PubMed ID: 30785037
[TBL] [Abstract][Full Text] [Related]
18. Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles.
Jang DJ; Moon C; Oh E
Biomed Pharmacother; 2016 May; 80():162-172. PubMed ID: 27133053
[TBL] [Abstract][Full Text] [Related]
19. Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles.
Kim C; Kim S; Oh WK; Choi M; Jang J
Chemistry; 2012 Apr; 18(16):4902-8. PubMed ID: 22422377
[TBL] [Abstract][Full Text] [Related]
20. Acid-responsive nanoparticles as a novel oxidative stress-inducing anticancer therapeutic agent for colon cancer.
Zhao C; Cao W; Zheng H; Xiao Z; Hu J; Yang L; Chen M; Liang G; Zheng S; Zhao C
Int J Nanomedicine; 2019; 14():1597-1618. PubMed ID: 30880968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
